The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
there's this sense that you know Ms conton is a drug for this subset of people who are in experiencing terrible cancer pain there's a much bigger community of people um who have uh moderate pain but the weirdness of it is that they then take a drug that is strong ER not weaker and Market it that way
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
let's just figure out a way to make everybody who doesn't have cancer takes this drug right and in fact to kind of to to sort of create the need which is you know a big part of what the marketing ended up being